TOday’s Movers: Biolinerx (NASDAQ:BLRX) Stock Rating Reaffirmed by Analysts at Oppenheimer; $3.0 Target Price Indicates 185.71 % Potential

September 17, 2017 - By Maria Brooks

 TOday’s Movers: Biolinerx (NASDAQ:BLRX) Stock Rating Reaffirmed by Analysts at Oppenheimer; $3.0 Target Price Indicates 185.71 % Potential

Biolinerx (NASDAQ:BLRX) Rating Reaffirmed

Oppenheimer now has a $3.0 target price on shares of Biolinerx (NASDAQ:BLRX). The target price indicates a potential upside of 185.71 % from the previous close of Biolinerx (NASDAQ:BLRX). This rating was released in a report on Tuesday, 12 September.

Bioline RX Ltd (NASDAQ:BLRX) Ratings Coverage

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx has $7 highest and $3.0 lowest target. $3.83’s average target is 264.76% above currents $1.05 stock price. BioLineRx had 14 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, May 18 by Maxim Group. TH Capital maintained the stock with “Buy” rating in Monday, July 27 report. Maxim Group downgraded the shares of BLRX in report on Friday, August 12 to “Hold” rating. The stock of Bioline RX Ltd (NASDAQ:BLRX) has “Buy” rating given on Tuesday, August 8 by Oppenheimer. Maxim Group maintained it with “Buy” rating and $300 target in Tuesday, August 8 report. The stock of Bioline RX Ltd (NASDAQ:BLRX) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. Maxim Group maintained the shares of BLRX in report on Monday, July 10 with “Buy” rating. Roth Capital initiated Bioline RX Ltd (NASDAQ:BLRX) on Thursday, August 3 with “Buy” rating. The firm has “Buy” rating by Maxim Group given on Thursday, June 1. The stock of Bioline RX Ltd (NASDAQ:BLRX) has “Buy” rating given on Friday, May 26 by H.C. Wainwright.

The stock increased 0.96% or $0.01 on September 15, reaching $1.05. About 125,334 shares traded. Bioline RX Ltd (NASDAQ:BLRX) has declined 6.10% since September 17, 2016 and is downtrending. It has underperformed by 22.80% the S&P500.

Analysts expect Bioline RX Ltd (NASDAQ:BLRX) to report $-0.05 EPS on November, 28.They anticipate $0.03 EPS change or 37.50 % from last quarter’s $-0.08 EPS. After having $-0.05 EPS previously, Bioline RX Ltd’s analysts see 0.00 % EPS growth.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. The company has market cap of $109.32 million. The Company’s clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. It currently has negative earnings.

More notable recent Bioline RX Ltd (NASDAQ:BLRX) news were published by: which released: “Investors Waiting In BioLineRx” on July 18, 2017, also with their article: “BioLineRx: At Around $1, This Sleeper Biotech Stock Is A Strong Buy” published on July 13, 2017, published: “BioLineRx Moves a Regulatory Submission for BL-8040 Trial” on August 22, 2017. More interesting news about Bioline RX Ltd (NASDAQ:BLRX) were released by: and their article: “BioLineRx: Expands Cancer Pipeline Significantly By Acquiring Novel Drug …” published on March 27, 2017 as well as‘s news article titled: “BioLineRx – Undervalued With Significant Pipeline, Large Pharma Collaborations …” with publication date: February 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.